December 11, 2020
Authored and Edited by Richard Hildreth; Amanda K. Murphy, Ph.D.
On December 4, the PTAB designated as precedential its decision in Apple Inc. v. Uniloc 2017 LLC denying both institution and a motion for joinder of a follow-on copycat petition. IPR2020-00854, Paper No. 9 (P.T.A.B. Oct. 28, 2020).
Apple first filed an IPR petition challenging U.S. Patent No. 6,467,088 in 2018. After that petition was denied, the Board instituted a separate challenge in 2020 by Microsoft against the same patent. This institution led Apple to file a second IPR asserting identical art and challenges as those contained in Microsoft’s IPR, along with a motion to join Microsoft’s IPR. Uniloc argued that the Board should exercise its discretion to deny institution under Rule 314(a) and, accordingly, deny joinder under the Fintiv and General Plastic factors. In response, Apple argued that neither the Fintiv nor General Plastic factors applied because it sought to take an “inactive or understudy role” in Microsoft’s IPR.
The Board did not find Apple’s “understudy argument” persuasive, noting that if Microsoft settled, Apple would stand in to continue a proceeding that would otherwise be terminated, with the same effect as if Apple had brought the second challenge to the patent in the first instance. Describing this as “the kind of serial attack that General Plastic was intended to address,” the Board denied both institution and the motion for joinder.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.